Blue Trust Inc. Raises Stake in Hologic, Inc. $HOLX

Blue Trust Inc. lifted its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 9.0% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 8,322 shares of the medical equipment provider’s stock after purchasing an additional 685 shares during the quarter. Blue Trust Inc.’s holdings in Hologic were worth $542,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently bought and sold shares of HOLX. Greenleaf Trust increased its position in Hologic by 5.1% in the second quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider’s stock worth $233,000 after buying an additional 173 shares during the period. Beverly Hills Private Wealth LLC grew its stake in shares of Hologic by 3.6% in the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider’s stock worth $320,000 after purchasing an additional 180 shares in the last quarter. Allworth Financial LP grew its stake in shares of Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider’s stock worth $40,000 after purchasing an additional 216 shares in the last quarter. First American Bank grew its stake in shares of Hologic by 0.9% in the second quarter. First American Bank now owns 28,705 shares of the medical equipment provider’s stock worth $1,870,000 after purchasing an additional 245 shares in the last quarter. Finally, Integrated Advisors Network LLC grew its stake in shares of Hologic by 5.4% in the first quarter. Integrated Advisors Network LLC now owns 5,603 shares of the medical equipment provider’s stock worth $346,000 after purchasing an additional 289 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Hologic Trading Down 1.3%

Shares of HOLX stock opened at $67.76 on Monday. The stock has a 50-day simple moving average of $67.15 and a 200 day simple moving average of $63.33. Hologic, Inc. has a fifty-two week low of $51.90 and a fifty-two week high of $84.39. The stock has a market capitalization of $15.07 billion, a P/E ratio of 28.12, a P/E/G ratio of 2.32 and a beta of 0.63. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating the consensus estimate of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The business had revenue of $1.02 billion during the quarter, compared to analysts’ expectations of $1.01 billion. During the same quarter last year, the business posted $1.06 earnings per share. The company’s quarterly revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Insider Buying and Selling at Hologic

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the stock in a transaction on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the completion of the transaction, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. This trade represents a 10.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 1.88% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on HOLX shares. Royal Bank Of Canada raised Hologic from a “sector perform” rating to an “outperform” rating and increased their price target for the stock from $72.00 to $87.00 in a research note on Wednesday, August 6th. Stephens reissued an “overweight” rating and issued a $78.00 price target on shares of Hologic in a research note on Thursday, September 18th. Evercore ISI set a $78.00 price target on Hologic and gave the stock an “outperform” rating in a research note on Tuesday, October 7th. Mizuho set a $75.00 price target on Hologic in a research note on Thursday, July 31st. Finally, UBS Group increased their price target on Hologic from $65.00 to $70.00 and gave the stock a “neutral” rating in a research note on Thursday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $80.15.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.